Fatality risks for nosocomial outbreaks of Middle East respiratory syndrome coronavirus in the Middle East and South Korea

Jianping Sha1 · Yuan Li2 · Xiaowen Chen3 · Yan Hu1 · Yajin Ren1 · Xingyi Geng4 · Zhiruo Zhang5 · Shelan Liu6

Received: 25 July 2016 / Accepted: 12 September 2016 / Published online: 23 September 2016
© Springer-Verlag Wien 2016

Abstract Middle East respiratory syndrome coronavirus (MERS-CoV) was first isolated in 2012. The largest known outbreak outside the Middle East occurred in South Korea in 2015. As of 29 June 2016, 1769 laboratory-confirmed cases (630 deaths; 35.6 % case fatality rate [CFR]) had been reported from 26 countries, particularly in the Middle East. However, the CFR for hospital outbreaks was higher than that of family clusters in the Middle East and Korea. Here, we compared the mortality rates for 51 nosocomial outbreaks in the Middle East and one outbreak of MERS-CoV in South Korea. Our findings showed the CFR in the Middle East was much higher than that in South Korea (25.9 % [56/216] vs. 13.8 % [24/174], \( p = 0.003 \)). Infected individuals who died were, on average, older than those who survived in both the Middle East (64 years [25–98] vs. 46 years [2–85], \( p = 0.000 \)) and South Korea (68 years [49–82] vs. 53.5 years [16–87], \( p = 0.000 \)). Similarly, the co-morbidity rates for the fatal cases were statistically higher than for the non-fatal cases in both the Middle East (64.3 % [36/56] vs. 28.1 % [45/160], \( p = 0.000 \)) and South Korea (45.8 % [11/24] vs. 12.0 % [18/150], \( p = 0.000 \)). The median number of days from onset to confirmation of infection in the fatal cases was longer than that for survivors from the Middle East (8 days [1–47] vs. 4 days [0–14], \( p = 0.009 \)). Thus, older age, pre-existing concurrent diseases, and delayed confirmation increase the odds of a fatal outcome in nosocomial MERS-CoV outbreaks in the Middle East and South Korea.

Introduction

The first report of Middle East respiratory syndrome (MERS) was identified in Saudi Arabia in June 2012. The Middle East respiratory syndrome coronavirus (MERS-CoV) isolated from this patient was similar to severe acute respiratory syndrome coronavirus (SARS-CoV), which caused an epidemic in 2002–2003 [49]. Both novel viruses are single-stranded RNA viruses belonging to the genus Betacoronavirus [25, 48], and the diseases they cause share common clinical characteristics, including fever, cough, diarrhea, and shortness of breath [5].
As of 29 June 2016, the World Health organization (WHO) had been notified of 1769 laboratory-confirmed cases with MERS-CoV (globally), including at least 630 deaths; the case fatality rate (CFR) was 35.6 % (630/1769) [46]. A total of 26 countries in the world have been affected, including countries in the Middle East (Egypt, Iran, Jordan, Kuwait, Lebanon, Oman, Qatar, Saudi Arabia, United Arab Emirates, Yemen), Africa (Algeria, Tunisia), Europe (Austria, France, Germany, Greece, Italy, the Netherlands, Turkey, the United Kingdom), Asia (China, the Republic of Korea, Malaysia, Philippines, Thailand) and North America (United States) (http://www.who.int/emergencies/mers-cov/en/). So far, all cases of MERS have been linked through travel to or residence in countries in or near the Middle East. Generally, the Middle East is the primary region where MERS-CoV originates, circulates and is exported. In contrast, since the first report of SARS-CoV in China in 2003, a total of 8096 SARS cases, including 774 deaths, have been reported to WHO. These have involved 19 countries, predominantly in South East Asia, with only one case identified in Kuwait in 2003, and no cases were found in the Middle East since then (http://www.who.int/csr/sars/country/table2004_04_21/en/). The fatality risk for MERS-CoV is much higher than that for SARS-CoV, which has a CFR of 9.6 % [9, 24]. Furthermore, the CFR for patients with co-morbidities is greater (60 % in MERS vs. 46 % in SARS) than those without pre-existing diseases [49]. Generally, the CFR is attributed to both host factors and virus factors (e.g. virus replication and mutation) and local medical expertise [3, 14].

One unique common epidemiological characteristic of these two diseases is that the spread of both MERS-CoV and SARS-CoV infection has been largely driven by human-to-human transmission in healthcare settings [25]. Failures in infection prevention and control in healthcare settings have occasionally resulted in large numbers of secondary cases in nosocomial outbreaks. The earliest identified nosocomial MERS outbreak was traced back to March 2012 from clusters of severe respiratory illness among healthcare personnel (HCP) in Jordan [43]. Since then, a series of nosocomial MERS outbreaks in small numbers have been identified in the Middle East (Jordan in 2012, Saudi Arabia in 2014–2015) [1, 6, 10, 18, 36]. In 2015, the largest known outbreak of MERS outside the Middle East occurred in the Republic of Korea; as of 19 June 2015, 186 laboratory-confirmed cases, including 36 deaths, had been reported. This outbreak was associated with a traveller returning from the Middle East (http://www.cdc.gov/coronavirus/mers/about/index.html). Although the genome sequences of MERS-CoV isolates from the Republic of Korea are similar to those isolated from the Middle East (http://www.who.int/mediacentre/news/mers/briefing-notes/update-15-06-2015/en/), the epidemiology of MERS in South Korea is very different to that observed in the Middle East. On the one hand, a MERS-CoV isolate that was responsible for an outbreak in South Korea showed a higher transmissibility than other previous MERS-CoV isolates. The epidemic thus far has undergone four generations of infectious events in South Korea through nosocomial super-spreading episodes [11]. On the other hand, an overall CFR of only 19.4 % (36/186) in hospital-based outbreaks in South Korea is substantially lower than the overall CFR of cases, most of which originate in the Middle East [38 % (444/1163); 65.2 % (15/23)] [1, 6]. To date, it is not clear what has caused the observed differences between the CFRs of South Korea and the Middle East.

In this study, we conducted a preliminary mortality risk factor analysis for nosocomial MERS-CoV outbreaks in South Korea and the Middle East. The findings from this study might help to reduce the severity and number of deaths from hospital-clustered cases by leading to the adoption of appropriate control measures.

Materials and methods

In 2015, scientists in the Republic of Korea and China completed full-genome sequencing of coronaviruses from the MERS outbreak in Korea. The findings were analysed by a group of virologists convened by WHO, and preliminary results suggested that the MERS-CoV viruses isolated in the Republic of Korea were similar to those isolated in the Middle East (http://www.who.int/mediacentre/news/mers/briefing-notes/update-15-06-2015/en/). MERS-CoVs associated with the Korean and Middle East outbreak belong to lineage 5 of MERS-CoV, which has been the predominant infectious agent in Saudi Arabian camels since November 2014 [41]. The MERS-CoV variants associated with the recent outbreak of human infections in South Korea (e.g., ChinaGD01-v1/2015 and KOR/KNIH/002-05/2015) show the highest similarity (99.96–99.98 %, full genome) to a camel virus (Camel/Riyadh/Ry159/2015) sampled in March 2015, followed by the latest strain (KT026453) prevalent in Saudi Arabia (99.92 % identified) [26]. However, the MERS-CoVs in Korea have the ability to cause large outbreaks in environments that are different from that of the Middle East (http://www.who.int/emergencies/mers-cov/en/).

Ethical statement

The National Health and Family Planning Commission of China determined that the collection of data from one human MERS-CoV infection imported from Korea was part of the public health investigation of an outbreak and was exempt from institutional review board assessment.
All other MERS cases were obtained from publicly available data sources. All data were supplied and analysed without access to personal identifying information.

**Data sources**

Information on all laboratory-confirmed MERS cases was obtained from various publicly available sources, including WHO Global Alert and Response updates, documents officially released by the local health bureau, news releases from Middle Eastern and South Korean authorities, the Weekly Epidemiological Record, ProMed posts, and literature published from 1 April 2012 to 29 June 2016 (http://www.who.int/csr/don/archive/disease/coronavirus_infections/en/). The latest cases that had not been officially announced by WHO were identified by searching ProMed posts, which confirmed announcements by individual countries’ ministries of health. Based on the available data, we initially established a database of a line list of human nosocomial MERS outbreaks (Supplementary Tables S1, S2 and S3).

**Case definitions**

**MERS definitions**

According to the WHO’s 14 July 2015 interim reporting definition (http://www.who.int/csr/disease/coronavirus_infections/case_definition/en/), a person with MERS has a laboratory-confirmed MERS-CoV infection, irrespective of clinical signs or symptoms. A case may be laboratory-confirmed by detection of viral nucleic acid or serology. The presence of viral nucleic acid can be confirmed by either a positive reverse transcription polymerase chain reaction (RT-PCR) result on at least two specific genomic targets or a single positive target with sequencing of a second target. A case confirmed by serology requires demonstration of seroconversion in two samples, ideally taken at least 14 days apart, by enzyme-linked immunosorbent assay (ELISA), by indirect fluorescent antibody (IFA) screening, or by a neutralization assay [25, 49].

**MERS cluster definitions**

A direct epidemiological link with a confirmed MERS-CoV patient may include (1) healthcare-associated exposure, including providing direct care for MERS-CoV patients, working with healthcare workers infected with MERS-CoV, visiting patients or staying in the same close environment of individuals infected with MERS-CoV; (2) working together in close proximity or sharing the same classroom environment with individuals infected with MERS-CoV; or (3) travelling together with individuals infected with MERS-CoV in any kind of conveyance or living in the same household as individuals infected with MERS-CoV. In addition, the epidemiological link may have occurred within a 14-day period before or after the onset of illness in the case under consideration [25].

**Statistical analysis**

We used a comparative epidemiological analysis of the dates of onset of illness and the characteristics of the fatal and surviving cases. All statistical analysis was conducted using the Statistical Analysis System, version 9.2 (SAS Institute, Cary, NC, USA). Quantitative measurements are presented as the median and range of the observed values, and qualitative measurements are presented as relative and absolute frequencies. An analysis of variance ($F$ test) was applied to the measurement data. $\chi^2$ tests were used to compare the distribution of the different variables of qualitative measurements between fatalities and survivors. Fisher’s exact test was used in the analysis of contingency tables when the sample sizes were small (the expected values in any of the cells of a contingency table were below 5; the number of total samples was no more than 40; the data were very unequally distributed among the cells of the table). Any $p$-values given were two-sided and considered statistically significant at 0.05.

**Results**

**Fatality risk factors for human clusters and sporadic cases of MERS-CoV infection**

As of 31 March 2016, we had identified 47 human laboratory-confirmed clusters with MERS-CoV, involving 179 cases, of which 53 were fatal. All clusters had been reported to WHO or published by the local authority or in PubMed. These MERS-clustered cases were distributed in nine countries: 29 clusters from the Kingdom of Saudi Arabia (KSA), six from the United Arab Emirates (UAE), four from Jordan, three from Qatar, and one each from France, Iran, Italy, Tunisia, and the United Kingdom (UK). The numbers of clusters per year were as follows: three clusters including 18 cases in 2012, 33 clusters including 108 cases in 2014, and 11 clusters including 53 cases in 2014.

For the control groups, we chose a total of 504 sporadic cases of MERS-CoV, composed of 129 fatal and 375 nonfatal cases from the following countries: 350 cases from the KSA, 125 cases from the UAE, 10 cases from Jordan, 10 from Qatar and 9 from Tunisia. The numbers of sporadic cases per year were as follows: 110 cases in 2012, 350 cases in 2013 and 44 cases in 2014.
The results showed that the percentages of HCP in MERS clusters were much higher than those in sporadic cases (32.4 % [58/179] vs. 10.7 % [54/504], \( p = 0.000 \)) (Table 1 and Table S1). However, the HCP-specific CFR was much lower than the overall CFR from MERS clusters (5.6 % [3/54] vs. 29.6 % [53/179], \( p = 0.000 \)) and sporadic cases (7.4 % [4/54] vs. 25.6 % [129/504], \( p = 0.003 \)) (Table 1).

Of the 53 fatal cases analysed in the MERS cluster groups, 67.9 % (36/53) had concurrent health conditions, which was a much higher percentage than that for nonfatal cases (22.2 % [28/126], \( p = 0.000 \)). A similar result was obtained for the sporadic groups (66.7 % [86/129] vs. 33.3 % [125/375], \( p = 0.000 \)). However, the percentage of co-morbidities in fatal and nonfatal infections of HCP was much lower than that for fatal cases overall (67.9 % [36/53] vs. 22.2 % [28/126], \( p = 0.001 \)) and nonfatal cases in the cluster groups (33.3 % [1/3] vs. 7.8 % [4/51], \( p = 0.000 \)) (Table 1).

The mean age in the fatal cases was significantly higher than in the nonfatal cases in the clustered cases (57 years [range 19–94] vs. 38 years [range 2–86], \( p = 0.000 \)) and sporadic cases (60 years [range 0–94] vs. 46 years [range 2–90], \( p = 0.000 \)). In contrast, the mean age of the survivors in clusters was slightly lower than in sporadic cases (38 years [range 2–86] vs. 46 years [range 2–90], \( p = 0.000 \)). The median age in fatal cases in HCP was much lower than in fatal cases overall (46.5 years [33–56] vs. 57 years [19–94], \( p = 0.000 \)) (Table 1).

We stratified the age groups between the fatal and nonfatal cases groups. The results showed a statistical difference in the distribution of the 0–14, 15–29, 30–44, and 60+ year-olds between the two groups (\( p = 0.000 \)). Males dominated both the fatal and nonfatal groups of the clustered and sporadic cases (\( p > 0.05 \)) (Table 1).

A history of exposure to camels prior to onset of disease was not significantly correlated with survival (7.5 % [4/53] vs. 5.6 % [7/126], \( p = 0.612 \)). Similarly, there was no significant correlation between survival and exposure to other animals, including sheep, goats, and horses (3.8 % [2/53] vs. 0.8 % [1/126], \( p = 0.156 \)). Similar results were found for the sporadic cases for exposure to camels (3.9 % [5/129] vs. 1.9 % [7/375], \( p = 0.197 \)) or to sheep, goats, and horses (0.8 % [1/129] vs. 1.3 % [5/375], \( p = 0.614 \)). In contrast, the percentage of survivors infected by human-human transmission was slightly higher than in the group of fatal cases (92.9 % [117/126] vs. 64.2 % [34/53], \( p = 0.000 \)) (Table 1).

Five time periods useful for public health surveillance were evaluated. The median time from onset to confirmation of infection in the fatal groups was much longer than that for survivors in MERS clusters (12.5 days [2–19] vs. 9 days [0–24], \( p = 0.041 \)) and in sporadic MERS cases (12 days [1–41] vs. 9 days [0–30], \( p = 0.003 \)). However, there were no statistical differences in the median time from onset to hospital admission, onset to hospital discharge, and subsequent death or the number of hospitalized days between the fatal and nonfatal cases for the two groups (Table 1).

### Fatality risk factors in human nosocomial outbreaks of MERS-CoV infection in the Middle East and South Korea

By 30 March 2016, we had obtained data on 51 nosocomial outbreaks involved in 216 confirmed cases (all 51 nosocomial outbreaks were from the Middle East; the above 47 clusters were not included in these outbreaks), including Iran (one cluster), KSA (41 clusters), Jordan (three clusters), France (one cluster) and UAE (five clusters).

We also had one nosocomial outbreak with 174 confirmed cases with MERS-CoV in South Korea (Table 2 and Table S2). The observed average cluster size (174) for MERS from South Korea was much greater than that for the Middle East (4, range 2–28).

Human nosocomial outbreaks with MERS-CoV in the Middle East occur throughout the year and peak in the spring, especially February to April. MERS outbreaks in South Korea were reported from March to June 2015, concomitant with peaks in the reporting of MERS nosocomial outbreaks in the Middle East (Table 2).

The overall CFR of the nosocomial outbreaks with MERS-CoV in the Middle East (25.9 % [56/216]) was significantly higher than in South Korea (13.8 % [24/174]; \( p = 0.003 \)). In contrast, the HCP-specific CFR (4.2 % [3/71]) was slightly lower than the overall CFR in the Middle East (\( p = 0.000 \)). Only one healthcare worker had died of MERS as of 15 July 2015 in South Korea (HCP-specific CFR 3.2 % [1/31]) (Table 2).

The percentage of HCP in outbreaks with MERS-CoV in the Middle East was much higher than in South Korea (32.9 % [71/216] vs. 18.7 % [31/166], \( p = 0.002 \)), but the percentage visiting a hospital in the Middle East was lower (18.5 % [40/216] vs. 30.1 % [50/166], \( p = 0.008 \)). Interestingly, no difference was identified in the percentage of hospitalized patients (48.6 % [105/216] vs. 51.2 % [85/166], \( p = 0.615 \)) between these two areas (Table 2).

For the two groups, the percentage of co-morbidities in those that died was statistically greater than that for survivors (64.3 % [36/56] vs. 28.1 % [45/160], \( p = 0.000 \)) in the Middle East; 45.8 % (11/24) vs. 12.0 % (18/150), \( p = 0.000 \) in South Korea (Table 2).

The average age in the fatal groups was much higher than that in the survival groups (64 years old [25–98] vs.
46 years old [2–85], \( p = 0.000 \) in the Middle East group; 68 years old [49–82] vs. 53.5 years old [16–87], \( p = 0.000 \) in the South Korea group). The over-60-year-old groups had the highest proportion of deaths, while the 45-to-59-year-old groups had the largest number of survivors. We found no difference in the gender distribution between the fatal and nonfatal cases in these two groups (male vs. female ratio 2.5:1.0 vs. 1.28:1.0 in the fatal and nonfatal cases, respectively, from the Middle East, \( p = 0.057 \); 2.0:1.0 vs. 1.4:1.0 in the fatal and nonfatal cases, respectively, from Korea, \( p = 0.509 \) (Table 2). We found no difference between the fatal and nonfatal cases with respect to exposure to camels and other animals (horses, sheep and goats). In contrast, the level of human-human transmission was much higher in the nonfatal cases in the Middle East than in the fatal cases (86.3 % [138/160] vs. 57.1 % [32/56], \( p = 0.000 \)). The percentage of inter-human transmission was much higher in the fatal cases in South Korea than in the Middle East (57.1 % [32/56] vs. 100.0 % [24/24], \( p = 0.000 \) (Table 2).

The Middle East group showed a statistical difference between fatal and nonfatal cases for the median days from

| Characteristic | MERS clusters (N = 47 clusters, 179 cases) | MERS sporadic cases (N = 504) | Outgroup comparison |
|----------------|------------------------------------------|-------------------------------|---------------------|
|                | Fatal (n = 53)  | Nonfatal (n = 126) | \( p_1 \) value | Fatal (n = 129)  | Nonfatal (n = 375) | \( p_2 \) value | \( p_3 \) value | \( p_4 \) value |
| Case fatality rate | Overall CFR [% (no.)]  | 29.6 (53/179)  | -  | 25.6 (129/504)  | -  | 0.297  | -  | -  |
|                 | Male-specific CFR [% (no.)] | 31.7 (40/126)  | -  | 27.9 (84/301)  | -  | 0.425  | -  | -  |
|                 | HCP-specific CFR [% (no.)] | 5.6 (3/54)  | -  | 7.4 (4/54)  | -  | 0.696  | -  | -  |
| Percentage of HCP [% (no.)] | 32.4 (58/179) | - | 10.7 (54/504) | - | 0.000  | -  | -  |
| Concurrent health condition in overall cases [% (no.)] | 67.9 (36/53)  | 22.2 (28/126) | 0.000 | 66.7 (86/129)  | 33.3 (125/375) | 0.000 | 0.870 | 0.019 |
| Concurrent health condition in HCP [% (no.)] | 33.3 (1/3)  | 7.8 (4/51)  | 0.000 | 25.0 (1/4)  | 8.0 (4/50)  | 0.000 | 0.334 | 0.778 |
| Mean age overall (years) | 57 (19–94)  | 38 (2–86)  | 0.000 | 60 (0–94)  | 46 (2–90)  | 0.000 | 0.241 | 0.000 |
| Mean age HCP (years) | 46.5 (33–56)  | 37 (24–60)  | 0.000 | 41.5 (26–54)  | 39 (24–48)  | 0.000 | 0.333 | 0.431 |
| Percent of male cases [% (no.)] | 79.2 (42/53)  | 66.7 (84/126) | 0.092 | 65.1 (84/129)  | 56.8 (213/375) | 0.098 | 0.061 | 0.059 |
| Age group [% (no.)] | 0-14 | 0.0 (0/53)  | 7.1 (9/126)  | 0.000 | 1.6 (2/129)  | 2.9 (11/35)  | 0.000 | 0.000 | 0.000 |
|                  | 15-29 | 7.5 (4/53)  | 30.2 (38/126) | 0.000 | 6.2 (8/129)  | 18.7 (70/375) | 0.000 | 0.000 | 0.000 |
|                  | 30-44 | 18.9 (10/53)  | 32.5 (41/126) | 0.000 | 10.1 (13/129)  | 31.7 (119/375) | 0.000 | 0.000 | 0.000 |
|                  | 45-59 | 35.8 (19/53)  | 23 (29/126)  | 0.000 | 27.9 (36/129)  | 24.8 (93/375) | 0.000 | 0.000 | 0.000 |
|                  | 60+ | 37.7 (20/53)  | 7.1 (9/126)  | 0.000 | 54.3 (70/129)  | 21.9 (82/375) | 0.000 | 0.000 | 0.000 |
| Exposure history [% (no.)] | Exposure to any animal | 11.3 (6/53)  | 6.3 (8/126)  | 0.258 | 4.7 (6/129)  | 3.2 (12/375)  | 0.444 | 0.258 | 0.118 |
|                  | Exposure to a camel | 7.5 (4/53)  | 5.6 (7/126)  | 0.612 | 3.9 (5/129)  | 1.9 (7/375)  | 0.197 | 0.299 | 0.030 |
|                  | Exposure to sheep or goats or horses | 3.8 (2/53)  | 0.8 (1/126)  | 0.156 | 0.8 (1/129)  | 1.3 (5/375)  | 0.614 | 0.149 | 0.630 |
| Human-human transmission | 64.2 (34/53)  | 92.9 (117/126) | 0.000 | 0.0 (0/129)  | 0.0 (0/375)  | -  | 0.000 | 0.000 |
| Disease progression (days) | From onset to admission | 4 (0–14)  | 4 (0–17)  | 0.661 | 5 (0–30)  | 5 (0–26)  | 0.553 | 0.239 | 0.788 |
|                  | From onset to confirmation | 12.5 (2–19)  | 9 (0–24)  | 0.041 | 12 (1–41)  | 9 (0–30)  | 0.003 | 0.874 | 0.975 |
|                  | From onset to death | 15 (3–51)  | -  | -  | 15 (1–40)  | -  | 0.819  | -  | -  |
|                  | From onset to discharge | -  | 12 (6–28)  | -  | 14 (3–26)  | -  | 0.554  | -  | -  |
|                  | Hospitalized days | 11 (0–35)  | 8 (4–16)  | 0.531 | 13 (0–39)  | 10 (2–23)  | 0.428 | 0.251 | 0.489 |

\( p_1 \): comparison of fatal and nonfatal cases in MERS clusters; \( p_2 \): comparison of fatal and nonfatal cases in MERS sporadic cases

\( p_3 \): comparison of fatal cases in MERS clusters and sporadic cases; \( p_4 \): comparison of nonfatal cases in MERS clusters and sporadic cases CFR, case fatality rate; HCP, healthcare personnel; ‘’’’, no data available
Table 2  Epidemical and clinical comparison of the fatal and nonfatal cases in human nosocomial outbreaks with MERS-CoV in the Middle East and South Korea as of 31 March 2016

| Characteristic               | Nosocomial outbreaks in the Middle East (N = 51 clusters, 216 cases) | Nosocomial outbreaks in South Korea (N = 1 cluster, 174 cases) | Outgroup comparison |
|-----------------------------|---------------------------------------------------------------------|-----------------------------------------------------------------|--------------------|
|                             | Fatal (n = 56) | Nonfatal (n = 160) | \( p_1 \) value | Fatal (n = 24) | Nonfatal (n = 150) | \( p_2 \) value | \( p_d \) value |
| Epidemical features         |                                                     |                                                                  |                    |
| Nosocomial outbreaks        |                                                     |                                                                  |                    |
| Cluster size                | 4 (2–28)                                               | -                                                               | 174 (174)          | -                   | -         |
| Cluster year                | 2012–2016                                              | -                                                               | 2015               | -                   | -         |
| Peak season                 | February–May                                           | -                                                               | April–May          | -                   | -         |
| Country                     | KSA (41 clusters)                                      | -                                                               | South Korea        | -                   | -         |
|                             | UAE (5 clusters)                                       |                                                                  |                    |
|                             | Jordan (3 clusters)                                    |                                                                  |                    |
|                             | France (1 cluster)                                     |                                                                  |                    |
|                             | Iran (1 cluster)                                       |                                                                  |                    |
| Case fatality rate [% (no.)] |                                                      |                                                                  |                    |
| Overall CFR                 | 25.9 (56/216)                                          | -                                                               | 13.8 (24/174)      | -                   | 0.003     |
| HCP-specific CFR            | 4.2 (3/71)                                             | -                                                               | 3.2 (1/31)         | -                   | 0.137     |
| Patient composition [% (no.)]|                                                      |                                                                  |                    |
| Percentage HCP              | 32.9 (71/216)                                          | -                                                               | 18.7 (3/166)       | -                   | 0.002     |
| Percentage visiting a patient at a healthcare facility | 18.5 (40/216)                                         | -                                                               | 30.1 (5/166)       | -                   | 0.008     |
| Percentage of hospitalized patients | 48.6 (105/216)                                       | -                                                               | 51.2 (85/166)      | -                   | 0.615     |
| Co-morbidities [% (no.)]    |                                                      |                                                                  |                    |
| Mean age (years)            | 64 (25–98)                                             | 46 (2–85)                                                       | 68 (49–82)         | 53.5 (16–87)        | 0.000     |
| Percentage of male cases [% (no.)] | 71.4 (40/56)                                       | 56.8 (90/160)                                                  | 66.7 (16/24)       | 58.7 (88/150)       | 0.509     |
| Age groups [% (no.)]        |                                                      |                                                                  |                    |
| 0-14                        | 0.0 (0/56)                                             | 1.1 (1/89)                                                     | <0.001             | 0.0 (0/24)          | 0.0 (0/150)| 0.000     |
| 15-29                       | 5.4 (3/56)                                             | 14.6 (13/89)                                                   | 0.0 (0/24)         | 5.3 (8/150)         | 0.000     |
| 30-44                       | 12.5 (7/56)                                            | 32.6 (29/89)                                                   | 0.0 (0/24)         | 28.7 (43/150)       | 0.000     |
| 45-59                       | 32.1 (18/56)                                           | 37.1 (33/89)                                                   | 20.8 (5/24)        | 32.0 (48/150)       | 0.000     |
| 60+                         | 50.0 (28/56)                                           | 14.6 (13/89)                                                   | 79.2 (19/24)       | 34.0 (51/150)       | 0.000     |
| Gender ratio (male:female)  | 2.5:1.0                                                | 1.28:1.0                                                        | 2:1.0              | 1.4:1.0             | 0.509     |
| Exposure history [% (no.)]  |                                                      |                                                                  |                    |
| Exposure to an animal        | 10.7 (6/56)                                            | 11.25 (18/160)                                                 | 1.000              | 0.0 (0/24)          | 0.0 (0/150)| -         |
| Exposure to a camel          | 8.9 (5/56)                                             | 8.8 (14/160)                                                   | 0.968              | 0.0 (0/24)          | 0.0 (0/150)| -         |
| Human-human transmission     | 57.1 (32/56)                                           | 86.3 (138/160)                                                 | 100.0 (24/24)      | 99.3 (149/150)      | 1.000     |
| Clinical features            |                                                      |                                                                  |                    |
| Disease progress (days)      |                                                      |                                                                  |                    |
onset to confirmation (8 days [1–47] vs. 4 days [0–14]; \( p = 0.009 \)) and hospitalized days (10 days [2–35] vs. 6.5 days [2–35], \( p = 0.004 \)). However, there was no significant difference between fatal and survival cases from South Korea. There were more hospitalized days for non-fatal cases from South Korea than for those cases from the Middle East (15 days [6–39] vs. 6.5 days [2–35], \( p = 0.035 \)) (Table 2).

## Fatal risk factors for index and secondary cases in nosocomial outbreaks of MERS-CoV infection in the Middle East

We determined the characteristics of the nonfatal and fatal index and secondary cases from 51 human nosocomial outbreaks of MERS-CoV infection in the Middle East as of 31 March 2016.

The CFR in the index cases was statistically higher than that of secondary cases (47.1 % [24/51] vs. 19.4 % [32/165], \( p = 0.000 \)). However, there were no differences in the percentage of total deaths between the index and secondary cases (Table 3).

The mean age of the deaths was significantly higher than that of the survival cases for the index (64 years [25–98] vs. 54 years [24–85], \( p = 0.038 \)) and secondary cases (43 years [2–85] vs. 37 years [2–86], \( p = 0.030 \)). Patients in the age groups \( \geq 60 \) and 45–59 years were the most common in the fatal and survival cases, respectively, for the index group, while the 45–59 and 30–44-year age groups were the common groups in the fatal and nonfatal cases, respectively, for the secondary cases. There was no significant difference in gender distribution between the fatal and nonfatal cases in the index and secondary groups (Table 3).

The ratio of co-morbidity was much higher in the fatal groups than in the non-fatal groups from the secondary cases (37.5 % [12/32] vs. 17.1 % [19/111], \( p = 0.026 \)); however, there was no difference between the fatal and nonfatal groups from the index cases. Similarly, a history of exposure prior to onset was common for the fatal and nonfatal cases from the index and secondary groups (Table 3).

There were no differences between fatal and nonfatal cases in the median time from onset to hospitalization, onset to confirmation, onset to discharge or death or hospitalized days (Table 3). However, the median time from onset to hospitalization was shorter in the secondary cases compared to the index cases (3 days [0–10] vs. 4 days [0–14] for the fatal cases, \( p = 0.035 \); 2 days [0–9] vs. 5 days [0–11] for the nonfatal cases, \( p = 0.009 \)). Similar results were found for the median time from onset to confirmation (3 [0–14] vs. 5 days [0–14] for nonfatal cases, \( p = 0.024 \)). The median time from onset to death in

### Table 2 continued

| Characteristic | Fatal (\( n = 56 \)) | Nonfatal (\( n = 160 \)) | Fatal (\( n = 24 \)) | Nonfatal (\( n = 150 \)) | \( p_1 \) value | \( p_2 \) value | \( p_3 \) value | \( p_4 \) value |
|---------------|-------------------|-------------------|-------------------|-------------------|-------------|-------------|-------------|-------------|
| Incubation    | 5 (3–7)           | 4.5 (2–9)         | 6 (1–15)          | 6 (1–15)          | 0.0905      | 0.072       | 0.0905      | 0.072       |
| From onset to admission | 4 (0–9)           | 3 (0–11)          | 4 (0–25)          | 4 (0–25)          | -           | -           | -           | -           |
| From onset to death | 11.5 (4–13)       | 14 (5–13)         | 17 (7–28)         | 15 (6–39)         | 0.004       | 0.004       | 0.004       | 0.004       |
| Hospitalized days | 10 (2–35)         | 6.5 (2–35)        | 10 (0–22)         | 10 (0–22)         | -           | -           | -           | -           |
| CFR, case fatality rate; HCP, healthcare personnel; KSA, Kingdom of Saudi Arabia; UAE, United Arab Emirates; '-' , no data available

**Notes:**
- \( p_1 \) value: comparison of fatal and nonfatal cases of MERS nosocomial outbreaks in the Middle East
- \( p_2 \) value: comparison of fatal and nonfatal cases of MERS nosocomial outbreak in South Korea
- \( p_3 \) value: comparison of fatal cases in MERS nosocomial outbreak in South Korea vs. the Middle East
- \( p_4 \) value: comparison of nonfatal cases in MERS nosocomial outbreak in South Korea vs. the Middle East
the secondary cases was slightly shorter than in the index cases (9 days [1–27] vs. 14 days [3–36], \( p = 0.033 \); however, the median time from onset to hospital discharge for secondary survivors was 10 days (6–18), which was significantly shorter than the 14 days (3–31) for index survivors \( p = 0.025 \).

**Discussion**

Acute respiratory tract infections with MERS-CoV cause considerable morbidity and mortality and pose a threat of repeated outbreaks in healthcare facilities [1, 6, 10, 18–20, 38]. The resulting transmission among patients, visitors, and HCP has been a defining feature of MERS-CoV epidemiology since its emergence in 2012 [7]. In this study, we compared the mortality risk factors in two different nosocomial outbreaks, based on 51 nosocomial outbreaks of MERS-CoV infection in the Middle East and one large outbreak identified in South Korea.

Our findings showed the final CFR for the Middle East (25.9 %) was significantly higher than that for South Korea (13.8 %). Both estimated CFRs were significantly lower than that for one hospital outbreak of MERS (CFR 65 % [15/23]) in Saudi Arabia in 2013 and another nosocomial outbreak (CFR 36.5 % [93/255]) in Saudi Arabia 2014 [5, 36]. The CFR of this latter outbreak was also much higher than that of one extended family cluster (10.5 % [2/19]) in Saudi Arabia in 2014 [4]. These results demonstrate that the survival rate of clustered patients with MERS-CoV in Korea was higher than in the Middle East. There are several possible explanations for the observed differences between the CFRs in South Korea and the Middle East. First, there may be disparities in national surveillance and available expertise [30]. Second, the CFR for the Middle East might have been overestimated because a large

---

**Table 3** Demographic characteristics of fatal and nonfatal index and secondary cases in human nosocomial outbreaks of MERS-CoV infection in the Middle East as of 31 March 2016

| Characteristic                  | Index cases (N = 51) | Secondary cases (N = 165) |
|--------------------------------|---------------------|--------------------------|
|                                | Fatal \( (n = 24) \) | Nonfatal \( (n = 27) \) | Fatal \( (n = 32) \) | Nonfatal \( (n = 130) \) |
| Percentage of total deaths [% (no.)] | 42.9 (24/56) | - | 57.1 (32/56) | 0.131 |
| CFR in cluster cases [% (no.)] | 47.1 (24/51) | - | 19.4 (32/165) | 0.000 |
| Median age [Years (range)] | 64 (25–98) | 54 (24–85) | 0.038 | 43 (2–85) | 37 (2–86) | 0.030 |

| Age group | 0–14 | 15–29 | 30–44 | 45–59 | 60+ |
|-----------|------|-------|-------|-------|-----|
|           | 0.0 (0/24) | 4.2 (1/24) | 16.7 (4/24) | 20.8 (5/24) | 58.3 (14/24) |
|           | 0.0 (0/27) | 3.7 (1/27) | 22.2 (6/27) | 51.9 (14/27) | 22.2 (6/27) |
|           | 0.000 | 0.000 | 0.000 | 28.1 (9/32) | 12.5 (4/32) |
|           | 3.1 (1/32) | 21.9 (7/32) | 21.9 (7/32) | 34.4 (11/32) | 12.5 (4/32) |
|           | 8.0 (9/113) | 35.4 (40/113) | 35.4 (40/113) | 21.2 (24/113) | 35.4 (40/113) |
| Gender | Female | Male | Female | Male |
|         | 16.7 (4/24) | 83.3 (20/24) | 31.2 (10/32) | 68.8 (22/32) |
|         | 22.2 (6/27) | 77.8 (21/27) | 37.5 (12/32) | 62.8 (71/113) |
|         | 0.618 | 0.731 | 0.618 | 0.731 |
|         | 0.000 | 0.000 | 0.000 | 0.000 |
| Co-morbidities [% (no.)] | 41.7 (10/24) | 4.3 (1/24) | 25.0 (6/24) | 6.9 (2/27) |
|         | 66.7 (18/27) | 77.8 (21/27) | 39.6 (8/27) | 77.8 (21/27) |
|         | 0.073 | 0.731 | 0.073 | 0.731 |
|         | 0.000 | 0.000 | 0.000 | 0.000 |
| Exposure history [% (no.)] | Travel history | Animal exposure | Visiting the hospital |
|         | 8.3 (2/24) | 8.3 (2/24) | 25.0 (6/24) |
|         | 11.1 (3/27) | 7.4 (2/27) | 39.6 (8/27) |
|         | 0.739 | 0.902 | 0.762 |
|         | 0.0 (0/32) | 3.1 (1/32) | 100.0 (32/32) |
|         | 0.9 (1/111) | 4.5 (5/111) | 100.0 (32/32) |
| Median days (days) | Days from onset to hospitalization | Days from onset to confirmation | Days from onset to death | Days from onset to discharge |
|         | 4 (0–14) | 6 (0–25) | 14 (3–36) | - |
|         | 5 (0–11) | 5 (0–14) | 3 (1–27) | 14 (3–31) |
|         | 0.496 | 0.802 | 0.000 | 0.000 |
|         | 3 (0–10) | 6 (2–19) | 9 (1–27) | 10 (3–31) |
|         | 2 (0–9) | 3 (0–14) | - | 10 (6–18) |
|         | 0.142 | 0.079 | - | - |
| Hospitalized days | 12 (2–35) | 12 (0–29) | 7 (4–16) | 8 (5–16) |
|         | 0.413 | 0.000 | 0.684 | 0.000 |

\( p_1 \): comparison of fatal and nonfatal index cases of MERS nosocomial outbreaks in the Middle East

\( p_2 \): comparison of fatal and nonfatal secondary cases of MERS nosocomial outbreaks in the Middle East
number of mild and asymptomatic cases are likely to go undetected there [37]. Third, it is possible that primary cases accounted for a higher percentage of the cluster patients in the Middle East than in South Korea [36].

The findings on age were consistent in hospital outbreaks in the Middle East and from South Korea. Our results showed that the median age in fatal cases was much higher than that in nonfatal cases. This is in agreement with a Saudi Arabian case series report that showed individuals older than 65 years had a greater association with mortality. A multivariate logistic regression model estimated that for every 1-year increase in age, the odds of dying increased by 12 % [29]. In all, this indicates that older age is associated with death in cases of MERS-CoV infection [12, 17, 44]. In particular, the median age in fatal HCP cases was also much higher than that in nonfatal HCP cases, but lower than the overall average. This is in agreement with the findings of Liu et al. [25]. The reasons for the higher fatality rates in older individuals are not understood but have been attributed to cultural practices that result in an increase in the exposure risk that older people are willing to take [37]. In addition, older people may be more likely to smoke and to have underlying diseases and impaired immune functions, which may increase susceptibility and progression of infections and even increase the chance of death [45].

The sex characteristics of MERS outbreaks in the Middle East are similar to those in South Korea. The patients in MERS outbreaks in both areas were predominantly male, and the proportion of males in the study populations did not differ [25]. Furthermore, there was no difference in the male-specific CFR between the MERS clusters of the two groups, a finding that is similar to other reports [1, 2, 10, 18]. Our findings suggest that the gender distribution is not linked to a fatal risk factor in MERS outbreaks.

HCP are at high risk of acquiring emerging MERS infections due to occupational exposure and are affected mostly by nosocomial outbreaks [1, 6, 15, 28, 35]. Based on previous outbreaks in the Middle East, HCP-related infections with MERS-CoV have been reported to range from 1 % to 34.2 % [7, 15]. Our findings showed that the percentage of HCP infections in MERS clusters was much higher than in sporadic cases [32.4 % vs. 10.7 %]. The recent outbreak in Jeddha demonstrated that the CFR among HCPs was only 3.7 % (4/109) [43]. Our findings suggest that the HCP-specific CFR was much lower than the overall CFR in both the Middle East [4.2 % vs. 25.9 %] and South Korea [3.2 % vs. 19.4 %]. However, the CFR of MERS in HCP has been reported to be up to 15.4 % (2/13) in four healthcare facilities of Saudi Arabia [7]. In total, the fatality risk for HCP was significantly lower than the overall fatality risk in the Middle East and South Korea. These findings can be attributed to three facts: first, the majority of HCP developed asymptomatic or mild symptoms and moderate symptoms [15]; second, HCP were confirmed as secondary cases under medical investigation, which led to earlier confirmation and good outcomes [32]; third, epidemiological analysis showed that HCP were much younger and had fewer co-morbidities compared to total MERS cases [36].

In contrast with SARS, about 75 % of patients with MERS had at least one additional illness, and patients who died were more likely to have an underlying condition (86 % of patients who died vs. 42 % of recovered or asymptomatic patients) [47, 49]. Similar to the Middle East, this study showed that the odds of dying were four times higher for individuals with concurrent health conditions than for those without these conditions in South Korea. The odds of fatality were much lower than those estimated by the logistic regression model (seven times) [29]. This is in part due to higher viral loads in the respiratory tract and longer shedding in patients with underlying diseases compared to cases without co-mortalities [33, 49].

Human-to-human transmission of MERS-CoV has been confirmed by epidemiological and genomic studies of cases associated with hospital and household MERS outbreaks [13]. Spread was assumed to occur largely via large droplets and contact [36]. Our study indicated that the percentage of human-to-human transmission in nonfatal cases was slightly higher (92.9 % vs. 64.2 %) than in fatal cases in MERS clusters, and two reasons could explain this: first, the survivors in secondary cases were younger and had fewer co-morbidities [11, 19, 20, 29, 38]; second, most of the secondary cases were under medical investigation, and therefore, the infection could be confirmed early once symptoms were observed, making timely treatment possible [16, 19, 20, 23, 36, 39, 42]. Overall, human-to-human transmission seems to have had a positive effect on the outcome of the secondary cases from the MERS nosocomial outbreaks in the Middle East. Rapid diagnosis and providing supportive care may be of marginal consequence in the MERS clusters [25, 29].

The progression of illness in fatal and nonfatal infections in nosocomial outbreaks with MERS-CoV in the Middle East does not follow the typical pattern of South Korea infections [29]. In the Middle East, the median time from onset to confirmation in fatal cases (8 days) was clearly longer than in nonfatal cases (4 days). In South Korea, however, there was no difference in the median time between fatal and nonfatal cases. This is consistent with other retrospective studies of MERS virus infections [6, 30, 36]. Furthermore, the time between suspected symptom onset and laboratory confirmation (6.5 days) in the fatal clusters was also slightly longer than the overall average [38]. In particular, this finding indicated that
delayed confirmation is a high-risk factor for human nosocomial outbreaks with MERS-CoV in the Middle East.

In conclusion, the overall CFR for nosocomial outbreaks in the Middle East was much higher than in South Korea. However, the mortality risk factors for MERS infections in the Middle East were similar to those identified for nosocomial outbreaks in South Korea. Older age, underlying diseases and delayed confirmation were the major risk factors for fatal outcome in human nosocomial outbreaks. In contrast, person-to-person transmission was associated with a good outcome for secondary cases during nosocomial outbreaks. Interestingly, gender, exposure history and median days were not indicators of death with MERS nosocomial outbreaks. The severity of nosocomial outbreaks and the risk of fatal infection in HCP were significantly lower than the overall rate in the Middle East and South Korea. Nosocomial outbreaks of MERS-CoV infection are associated with knowledge deficits, unrecognized disease, insufficient infection control measures, poor compliance, and an overwhelming number of patient cases [21, 22, 34, 40, 45]. Therefore, early and rapid detection of suspected cases, especially in older people and HCP, along with appropriate infection control practices, education and timely preparedness, are important strategies to reduce nosocomial transmission and to improve the clinical outcome in health settings in the future [8, 27, 31, 35].

Acknowledgements We thank the reporting countries with the confirmed MERS cases. We appreciate their assistance with field investigations, administration and data collection and sending the data to WHO.

Compliance with ethical standards

Conflict of interest None declared.

References

1. Al-Abdallat MM, Payne DC, Alqasrawi S, Rha B, Tohme RA, Abedi GR, Al Nsour M, Iblan I, Jarour N, Farag NH, Haddadin A, Al-Sanouri T, Tamin A, Harcourt JL, Kuhar DT, Sverdlow DL, Erdman DD, Pallansch MA, Haynes LM, Gerber SI, Jordan M-CIT (2014) Hospital-associated outbreak of Middle East respiratory syndrome coronavirus: a serological, epidemiological, and clinical description. Clin Infect Dis Off Publ Infect Dis Soc Am 59:1225–1233.
2. Al-Tawfiq JA, Hinedi K, Ghandour J, Khairalla H, Musleh A, Ujaili A, Memish ZA (2014) Middle East respiratory syndrome coronavirus: a case-control study of hospitalized patients. Clin Infect Dis Off Publ Infect Dis Soc Am 59:160–165.
3. Alraddadi BM, Watson JT, Almarashi A, Abedi GR, Turkistani A, Sadran M, Houa S, Almazroa MA, Alraihan N, Banjar A, Albalawi E, Alhindhi H, Choudhry AJ, Meiman JG, Paczkowski M, Curns A, Mounts A, Feikin DR, Marano N, Sverdlow DL, Gerber SI, Hajjeh R, Madani TA (2016) Risk factors for primary Middle East respiratory syndrome coronavirus illness in humans, Saudi Arabia, 2014. Emerg Infect Dis 22:49–55.
4. Arwady MA, Alraddadi B, Basler C, Azhar EI, Abuelzein E, Sindy AI, Sadiq BM, Alhaqaf AO, Shabouni O, Banjar A, Haynes LM, Gerber SI, Feikin DR, Madani TA (2016) Middle East respiratory syndrome coronavirus transmission in extended family, Saudi Arabia, 2014. Emerg Infect Dis 22.
5. Assiri A, Al-Tawfiq JA, Al-Rabeaaah AA, Al-Rabiah FA, Al-Hajjar S, Al-Barrak A, Flemban H, Al-Nassir WN, Balkhy HH, Al-Hakeem RF, Makhdoom HQ, Zumla AI, Memish ZA (2013) Epidemiological, demographic, and clinical characteristics of 47 cases of Middle East respiratory syndrome coronavirus disease from Saudi Arabia: a descriptive study. Lancet Infect Dis 13:752–761.
6. Assiri A, McGeer A, Peri TM, Price CS, Al Rabeaaah AA, Cummings DA, Alabdullatif ZN, Assad M, Almulhim A, Makhdoom H, Madani H, Alhakeem R, Al-Tawfiq JA, Cotten M, Watson SJ, Kellam P, Zumla AI, Memish ZA, Team KM-CI (2013) Hospital outbreak of Middle East respiratory syndrome coronavirus. New Engl J Med 369:407–416.
7. Assiri A, Abedi GR, Bin Saeed AA, Abdalla MA, Al-Masyr M, Choudhry AJ, Lu X, Erdman DD, Tatti K, Binder AM, Rudd J, Tokars J, Miao C, Alarbash H, Noor H, Pallansch M, Gerber SI, Watson JT (2016) Multiplicity outbreak of Middle East respiratory syndrome in Taif, Saudi Arabia. Emerg Infect Dis 22:32–40.
8. Butt TS, Koulbakis-Barron I, AlJumaah S, AlThawadi S, AlMofada S (2016) Infection control and prevention practices implemented to reduce transmission risk of Middle East respiratory syndrome-coronavirus in a tertiary care institution in Saudi Arabia. Am J Infect Control.
9. Chong PY, Chui P, Ling AE, Franks TJ, Tai DY, Leo YS, Kaw GJ, Wansaicheong G, Chan KP, Ean Oon LL, Teo ES, Tan KB, Nakajima N, Sata T, Travis WD (2004) Analysis of deaths during the severe acute respiratory syndrome (SARS) epidemic in Singapore: challenges in determining a SARS diagnosis. Arch Pathol Lab Med 128:195–204.
10. Chowell G, Blumberg S, Simonsen L, Miller MA, Viboud C (2014) Synthesizing data and models for the spread of MERS-CoV, 2013: key role of index cases and hospital transmission. Epidemics 9:40–51.
11. Cowling BJ, Park M, Fang VJ, Wu P, Leung GM, Wu JT (2015) Preliminary epidemiological assessment of MERS-CoV outbreak in South Korea, May to June 2015. Euro Surveill Bull Eur sur les Maladies Transm Eur Commun Dis Bull 20:7–13.
12. Drosten C, Seilmaier M, Corman VM, Hartmann W, Scheible G, Sack S, Guggemos W, Kallies R, Muth D, Junglen S, Muller MA, Haas W, Guberina H, Rohnisch T, Schmid-Wendtner M, Aldabbagh S, Dittmer U, Gold H, Graf P, Bonin F, Rambaut A, Wendtner CM (2013) Clinical features and virological analysis of a case of Middle East respiratory syndrome coronavirus infection. Lancet Infect Dis 13:745–751.
13. Drosten C, Muth D, Corman VM, Hussain R, Al Masri M, Hajj Omar W, Landt O, Assiri A, Eckerle I, Al Shangiti A, Al-Tawfiq JA, Al Barrak A, Zumla A, Rambaut A, Memish ZA (2015) An observational, laboratory-based study of outbreaks of middle East respiratory syndrome coronavirus in Jeddah and Riyadh, kingdom of Saudi Arabia, 2014. Clin Infect Dis Off Publ Infect Dis Soc Am 60:369–377.
14. Feikin DR, Alraddadi B, Qutub M, Shabouni O, Curns A, Obolho IK, Tomczyk SM, Wolff B, Watson JT, Madani TA (2015) Association of higher MERS-CoV virus load with severe disease and death, Saudi Arabia, 2014. Emerg Infect Dis 21:2092–2035.
15. Hijawi B, Abdallat M, Sayaydeh A, Alqasrawi S, Haddadin A, Jaarour N, Alsheikh S, Alsanouri T (2013) Novel coronavirus infections in Jordan, April 2012: epidemiological findings from a retrospective investigation. Eastern Mediterranean
Health J. La revue de sante de la Mediterranee orientale al-Majallah al-sihhiyah li-ashar al-mutawassit 19(Suppl 1):S12–S18.

16. Hsieh YH (2015) 2015 Middle East respiratory syndrome coronavirus (MERS-CoV) nosocomial outbreak in South Korea: insights from modeling. PeerJ 3:e1505.

17. Hui AY, Chan HL, Liew CT, Chan PK, To KF, Chan CP, Sung JJ (2003) Fatal outcome of SARS in a patient with reactivation of chronic hepatitis B. Am J Med 115:334–336.

18. Khalid M, Khan B, Al Rabiah F, Alismaili S, Saleemi S, Rehan-Khalig AQ, Weheba I, Al Abdely H, Halim M, Nadri QJ, Al Dalaan AM, Zeitouni M, Butt T, Al Mutairy E (2014) Middle Eastern respiratory syndrome coronavirus (MERS-CoV): case reports from a tertiary care hospital in Saudi Arabia. Ann Saudi Med 34:396–400.

19. Ki M (2015) 2015 MERS outbreak in Korea: hospital-to-hospital transmission. Epidemiol Health 37:e2015033.

20. Kim KM, Ki M, Cho SI, Sung M, Hong JK, Cheong HK, Kim JH, Lee SE, Lee C, Lee KJ, Park YS, Kim SW, Choi BY (2015) Epidemiologic features of the first MERS outbreak in Korea: focus on Pyeongtaek St. Mary’s Hospital. Epidemiol Health 37:e2015041.

21. Lee N, Sung JJ (2003) Nosocomial transmission of SARS. Curr Infect Dis Rep 5:473–476.

22. Lee N, Chan PK, Yu IT, Tsoi KK, Liu CL, Cockram CS (2007) Co-circulation of human metapneumovirus and SARS-associated coronavirus during a major nosocomial SARS outbreak in Hong Kong. J Clin Virol 40:333–337.

23. Lim PL (2015) Middle East respiratory syndrome (MERS) in Asia: lessons gleaned from the South Korean outbreak. Trans R Soc Trop Med Hyg 109:541–542.

24. Liu M, Liang WN, Chen Q, Xie XQ, Wu J, He X, Liu ZJ (2006) Risk factors for SARS-related deaths in 2003, Beijing. Biomed Environ Sci BES 19:336–339.

25. Liu S, Chan TC, Chu YT, Wu JT, Geng X, Zhao N, Chen E, King CC (2016) Comparative epidemiology of human infections with Middle East respiratory syndrome and severe acute respiratory syndrome coronaviruses among Healthcare Personnel. PloS One 11:e0149988.

26. Lu R, Wang Y, Fang W, Nie K, Zhao Y, Su J, Deng Y, Zhou W, Li Y, Wang H, Wang W, Ke C, Ma X, Wu G, Tan W (2015) Complete genome sequence of Middle East respiratory syndrome coronavirus (MERS-CoV) from the first imported MERS-CoV case in China. Genome Announc 3.

27. Madani TA, Althaqafi AO, Alazzad MA (2014) Infection prevention and control guidelines for patients with Middle East respiratory syndrome coronavirus (MERS-CoV) infection. Saudi Med J 35:897–913.

28. Mailles A, Blankcaert K, Chaud P, van der Werf S, Lina B, Caro V, Campese C, Guery B, Prouvost H, Lemaire X, Paty MC, Haeghebaert S, Antoine D, Ettaher N, Noel H, Behillil S, Hendrix S, Manuguerra JC, Enouf V, La Ruche G, Semaille C, Coignon B, Levy-Bruhl D, Weber F, Saura C, Che D, investigation t (2013) First cases of Middle East Respiratory Syndrome Coronavirus (MERS-CoV) infections in France, investigations and implications for the prevention of human-to-human transmission, France, May 2013. Euro Surveill 18.

29. Majumder MS, Kluberg SA, Mekaru SR, Brownstein JS (2015) Mortality risk factors for Middle East respiratory syndrome outbreak, South Korea, 2015. Emerg Infect Dis 21:2088–2090.

30. Memish ZA, Zumla AI, Assiri A (2013) Middle East respiratory syndrome coronavirus infections in health care workers. N Engl J Med 369:884–886.

31. Memish ZA, Al-Tawfiq JA (2014) Middle East respiratory syndrome coronavirus infection control: the missing piece? Am J Infect Control 42:1258–1260.

32. Memish ZA, Al-Tawfiq JA, Mahdood HQ, Al-Rabeeah AA, Assiri A, Alhakeem RF, AlRabiah FA, Al Hajeer S, AlBarrack A, Flemban H, Balkhy H, Barry M, Alhassan S, Alsubaie S, Zumla A (2014) Screening for Middle East respiratory syndrome coronavirus infection in hospital patients and their healthcare worker and family contacts: a prospective descriptive study. Clin Microbiol Infect 20:469–474.

33. Memish ZA, Al-Tawfiq JA, Mahdood HQ, Assiri A, Alhakeem RF, AlBarrack A, Alsubaie S, Al-Rabeeah AA, Hajomar WH, Hassain R, Kheyami AM, Almaitur A, Azhaz E, Drosten C, Watson S, Kellam P, Cotten M, Zumla A (2014) Respiratory tract samples, viral load, and genome fraction yield in patients with Middle East respiratory syndrome. J Infect Dis 210:1590–1594.

34. Memish ZA, Assiri A, Alhakeem R, Yezi Z, Almasri M, Zumla A, Al-Tawfiq JA, Drosten C, AlBarrack A, Petersen E (2014) Middle East respiratory syndrome coronavirus virus, MERS-CoV. Conclusions from the 2nd Scientific Advisory Board Meeting of the WHO Collaborating Center for Mass Gathering Medicine. Riyadh Int J Infect Dis 24:51–53.

35. Memish ZA, Assiri AM, Al-Tawfiq JA (2014) Middle East respiratory syndrome coronavirus (MERS-CoV) viral shedding in the respiratory tract: an observational analysis with infection control implications. Int J Infect Dis 29:307–308.

36. Oboho IK, Tomczyk SM, Al-Asmari AM, Banjar AA, Al-Mugti H, Aloraini MS, Alkhaldi KZ, Almohammadi EL, Alraddadi BM, Gerber SI, Swerdlow DL, Watson JT, Madani TA (2015) 2014 MERS-CoV outbreak in Jeddah—a link to health care facilities. New Engl J Med 372:846–854.

37. Omran SI, Matin MA, Haddad Q, Al-Nakhli D, Memish ZA, AlBarrack AM (2013) A family cluster of Middle East Respiratory Syndrome Coronavirus infections related to a likely unrecognized asymptomatic or mild case. Int J Infect Dis 17:e668–e672.

38. Park HY, Lee EJ, Ryu YW, Kim Y, Kim H, Lee H, Yi SJ (2015) Epidemiological investigation of MERS-CoV transmission among healthcare workers in Hanoi, Vietnam, May to June 2015. Euro Surveill Bull Eur sur les maladies Transm Eur Commun Dis Bull 20:1–6.

39. Petersen E, Hui DS, Perlman S, Zumla A (2015) Middle East respiratory syndrome—advancing the public health and research agenda on MERS—lessons from the South Korea outbreak. Int J Infect Dis 36:54–55.

40. Reynolds MG, Anh BH, Thu VH, Montgomery JM, Bausch DG, Shah JJ, Maloney S, Leitmeyer KC, Huy VQ, Horby P, Plant AY, Uyeki TM (2006) Factors associated with nosocomial SARS-CoV transmission among healthcare workers in Hanoi, Vietnam, 2003. BMC Public Health 6:207.

41. Sabir JS, Lamm TT, Ahmed MM, Li L, Chen Y, Abo-Abu SE, Qureshi MI, Abu-Zeid M, Zhang Y, Khiyami MA, Alharbi NS, Hajrah NH, Sabir MJ, Mutwakil MH, Kabli SA, Alsaluaimany FA, Obaid AY, Zhou B, Smith TK, Holmes EC, Zhu H, Guan Y (2016) Co-circulation of three camel coronavirus species and recombinant MERS-CoV infections related to a likely unrecognized asymptomatic or mild case. Int J Infect Dis 17:e668–e672.

42. Sukumaran A, Patil S (2014) The MERS-CoV outbreak: challenges facing the dental profession. J Contemp Dent Pract 15:i–ii.

43. Uyeki TM, Shih JS, Hijjawi J, Khiyami MA, Alharbi NS, Dalaan AM, AlMutairy F, Al-Barrack A, Draboski AA, Draboski AA, Elhussaini A, Besada S, Obaid AY, Zhou B, Smith TK, Holmes EC, Zhu H, Guan Y (2016) Co-circulation of three camel coronavirus species and recombinant MERS-CoV in Saudi Arabia. Science 351:81–84.

44. Sukumaran A, Patil S (2014) The MERS-CoV outbreak: challenges facing the dental profession. J Contemp Dent Pract 15:i–ii.

45. Swaminathan N, Apisarnthanarak A (2015) Risks to healthcare workers with emerging diseases: lessons from MERS-CoV, Ebola, SARS, and avian flu. Curr Opin Infect Dis 28:349–361.

46. Wang H, Ding Y, Li X, Yang L, Zhang W, Kang W (2003) Fatal aspergillosis in a patient with SARS who was treated with corticosteroids. N Engl J Med 349:507–508.

47. Webb GF, Blaser MJ, Zhu H, Ardal S, Wu J (2004) Critical role of nosocomial transmission in the Toronto sars outbreak. Math Biosci Eng 1:1–13.
46. WHO (2016) Middle East respiratory syndrome coronavirus (MERS-CoV)
47. Mers-Cov Research G (2013) State of knowledge and data gaps of Middle East respiratory syndrome coronavirus (MERS-CoV) in humans. PLoS Curr 5
48. Yang L, Wu Z, Ren X, Yang F, Zhang J, He G, Dong J, Sun L, Zhu Y, Zhang S, Jin Q (2014) MERS-related betacoronavirus in Vespertilio superans bats, China. Emerg Infect Dis 20:1260–1262
49. Zumla A, Hui DS, Perlman S (2015) Middle East respiratory syndrome. Lancet 386:995–1007